Glactiv sitagliptin regulatory update

In May, Japan approved Glactiv sitagliptin to treat Type II diabetes in combination with alpha-glucosidase inhibitors. The dipeptidyl peptidase-4 (DPP-4) inhibitor is already marketed in Japan to tre...